Quarterly report pursuant to Section 13 or 15(d)

Liquidity and Financial Condition (Details Narrative)

v3.22.0.1
Liquidity and Financial Condition (Details Narrative) - USD ($)
 1 Months Ended 2 Months Ended 3 Months Ended 9 Months Ended
May 01, 2020
Jun. 24, 2020
Jun. 02, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Mar. 31, 2021
FinancialOverviewLineItems [Line Items]                
Net loss       $ 944,000 $ 650,000 $ 2,142,000 $ 290,000  
Net loss       944,000 $ 650,000 2,142,000 290,000  
Accumulated deficit       181,419,000   181,419,000   $ 179,277,000
Working capital       $ 13,824,000   13,824,000   $ 8,905,000
Cash received from sale of Micromed           0 610,000  
Forgiveness of PPP Loan           $ 723,000  
Stock issued during period, shares       94,600   950,100    
Gross proceeds from issuance of stock       $ 700,000   $ 7,901,000    
Net proceeds       $ 662,000   7,554,000 $ 0  
November 2018 Common Stock Purchase Warrants [Member]                
FinancialOverviewLineItems [Line Items]                
Proceeds from exercise of warrants     $ 1,799,000          
States Bank In Atlanta [Member] | Paycheck Protection Program [Member]                
FinancialOverviewLineItems [Line Items]                
Proceeds from Loans $ 1,310,000              
Debt Instrument, Maturity Date Apr. 29, 2022              
Debt Instrument, Interest Rate, Stated Percentage 1.00%              
Forgiveness of PPP Loan           $ 723,000    
Asset Purchase Agreement [Member]                
FinancialOverviewLineItems [Line Items]                
Aggregate sale price of Micromed division   $ 850,000            
Cash received from sale of Micromed   610,000            
Credit received for future testing services from sale of Micromed   100,000            
Sale of assets, amount held in escrow   60,000            
Accounts receivable remaining from sale of asset   $ 81,000